BMS-986256
Sponsors
Bristol-Myers Squibb
Conditions
Healthy ParticipantsLupus Erythematosus, Cutaneous
Phase 1
An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
CompletedNCT03634995
Start: 2018-08-14End: 2019-10-09Updated: 2020-06-16
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
CompletedNCT03950960
Start: 2019-05-02End: 2019-08-07Updated: 2020-02-25
A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants
CompletedNCT04016753
Start: 2019-08-05End: 2020-02-21Updated: 2022-05-31
Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil
CompletedNCT04039373
Start: 2019-07-22End: 2019-10-16Updated: 2020-06-16
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants
CompletedNCT04269356
Start: 2020-02-18End: 2021-03-30Updated: 2022-01-10
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
CompletedNCT04470778
Start: 2020-07-20End: 2021-03-28Updated: 2025-02-06
A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
CompletedNCT04493541
Start: 2020-08-26End: 2023-04-21Updated: 2023-05-09
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
CompletedNCT04941755
Start: 2021-06-25End: 2021-09-24Updated: 2022-01-21